USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MBIO DIAGNOSTICS, INC.
Address:
5603 Arapahoe Ave, Suite 1
BOULDER, CO 80303-1377
Phone:
N/A
URL:
N/A
EIN:
130059362
DUNS:
961776577
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $197,467.00 1
SBIR Phase II $3,030,183.00 2

Award List:

Point-of-Care HIV Antigen/Antibody Diagnostic Device

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$197,467.00
Agency:
HHS
Principal Investigator:
Michael J. Lochhead – 303-952-2810
Abstract:
DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based, 4th generation antigen/antibody clinical… More

Low Cost Laser Diagnostic for CD4+ T Cell Counting

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,641,802.00
Agency:
HHS
Principal Investigator:
Michael J. Lochhead – 303-952-2810
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop and commercialize a simple cell counter for routine enumeration of CD4 cells for management of HIV-infected individuals. HIV-1 mediated CD4 cell destruction is the centralimmunologic feature of HIV-1 infection.… More

Point-of-Care HIV Antigen/Antibody Diagnostic Device

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,388,381.00
Agency:
HHS
Principal Investigator:
Michael J. Lochhead – 303-952-2810
Abstract:
DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical… More